193 related articles for article (PubMed ID: 22975816)
1. [Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].
Koda Y; Mori T; Shimizu T; Kato J; Yamane A; Sadahira K; Tsukada Y; Yokoyama K; Hashimoto N; Hattori Y; Okamoto S
Rinsho Ketsueki; 2012 Aug; 53(8):760-4. PubMed ID: 22975816
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.
Perfetti V; Palladini G; Brunetti L; Sgarella A; Brugnatelli S; Gobbi PG; Corazza GR
Eur J Gastroenterol Hepatol; 2007 Jul; 19(7):599-601. PubMed ID: 17556909
[TBL] [Abstract][Full Text] [Related]
3. Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy.
Hashimoto N; Yokoyama K; Sadahira K; Ueda T; Tsukada Y; Okamoto S
Int J Hematol; 2012 Dec; 96(6):758-63. PubMed ID: 23179905
[TBL] [Abstract][Full Text] [Related]
4. [Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report].
Fukushima T; Iwao H; Sakai T; Sato T; Nakamura T; Nakajima A; Miki M; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Umehara H
Gan To Kagaku Ryoho; 2012 May; 39(5):805-7. PubMed ID: 22584336
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
Fukushima T; Nakamura T; Iwao H; Nakajima A; Miki M; Sato T; Sakai T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2011 Jun; 31(6):2297-302. PubMed ID: 21737655
[TBL] [Abstract][Full Text] [Related]
6. Multiple significant bortezomib-related toxicities in one patient: case report and literature review.
Waller JM; Moretto JC; Knopf KB
Clin Lymphoma Myeloma; 2009 Jun; 9(3):E1-4. PubMed ID: 19525183
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-induced skin eruption.
Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
[TBL] [Abstract][Full Text] [Related]
9. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
10. Strategy to reduce bortezomib-induced paralytic ileus in patients with myeloma and impaired renal function.
Keating M; Dasanu CA
BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27899388
[TBL] [Abstract][Full Text] [Related]
11. Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
Moon SJ; Min CK; Lee DG; Lee S; Lee JW; Min WS; Kim CC; Kim M; Park G; Kim Y
Acta Haematol; 2007; 117(4):211-4. PubMed ID: 17237615
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
13. [Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
Arai A; Oshikawa G; Kurosu T; Miki T; Tohda S; Koyama T; Murakami N; Miura O
Rinsho Ketsueki; 2006 Aug; 47(8):777-80. PubMed ID: 16986718
[TBL] [Abstract][Full Text] [Related]
14. [Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
Nakamura S; Yata K; Jinno T; Harada T; Fujii S; Miki H; Nakano A; Kagawa K; Takeuchi K; Ozaki S; Abe M; Matsumoto T
Rinsho Ketsueki; 2010 Aug; 51(8):690-5. PubMed ID: 20805677
[TBL] [Abstract][Full Text] [Related]
15. [Severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma].
Sanada Y; Nakazato T; Suzuki K; Mihara A; Aisa Y; Iwabuchi M; Kakimoto T
Rinsho Ketsueki; 2010 Apr; 51(4):264-9. PubMed ID: 20467223
[TBL] [Abstract][Full Text] [Related]
16. [Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
Fukushima T; Iwao H; Nakajima A; Miki M; Sakai T; Sawaki T; Tanaka M; Masaki Y; Hirose Y; Umehara H
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1387-9. PubMed ID: 19692786
[TBL] [Abstract][Full Text] [Related]
17. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
[TBL] [Abstract][Full Text] [Related]
18. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
19. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
Aguayo-Leiva I; Vano-Galvan S; Carrillo-Gijon R; Jaén-Olasolo P
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1363-4. PubMed ID: 20337821
[No Abstract] [Full Text] [Related]
20. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
